Presentation TCT 2016 TAVR Restenosis: Review of the Literature Presenter: Nick Curzen October 31, 2016
Presentation TCT 2016 Case #1: A TAVR Complication to Learn From Presenter: Antonio Colombo, Jeffrey W. Moses, Samir R. Kapadia October 31, 2016
Presentation TCT 2016 Surgical and Transcatheter Aortic Valve Replacement for Patients With Heart Failure and High and Low Gradient Aortic Stenosis: Magnitude of Benefit and Prediction of Responders Presenter: Jeroen J. Bax, Ileana L. Pina, Ori Ben-Yehuda October 31, 2016
Presentation TCT 2016 Case Introduction: An 87 Year Old Woman With Recurrent Dyspnea 7 Years After TAVR Presenter: Nick Curzen, Michael Mahmoudi October 31, 2016
Presentation TCT 2016 Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred! Presenter: Raj Makkar, Lars Sondergaard, Stephen J.D. Brecker October 31, 2016
Presentation TCT 2016 Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach! Presenter: Raj Makkar, Lars Sondergaard, Antonio Colombo October 31, 2016
Presentation TCT 2016 TAVR for Intermediate-Risk and Low-Risk Patients: Review of the Literature Presenter: Niall T. Mulvihill, Michael Mahmoudi October 31, 2016
Presentation TCT 2016 Controversy 4. Will the Minimalist Strategy Dominate TAVR in the Future: Supportive Clinical and Economic Data Presenter: Raj Makkar, Lars Sondergaard, Ganesh Manoharan October 31, 2016
Presentation TCT 2016 Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Con Position Presenter: Niall T. Mulvihill, Hellmuth Weich October 31, 2016
Presentation TCT 2016 Late (>5 years) Clinical and Echo Outcomes After TAVR II: The Vancouver Experience Presenter: Raj Makkar, Lars Sondergaard, John G. Webb October 31, 2016
Presentation TCT 2016 Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Pro Position Presenter: Niall T. Mulvihill, Antoniette Neylon October 31, 2016
Presentation TCT 2016 Introduction: TAVR in Intermediate-Risk and Low-Risk With Severe Aortic Stenosis Presenter: Niall T. Mulvihill October 31, 2016
Presentation TCT 2016 Late (>5 years) Clinical and Echo Outcomes After TAVR I: The Rouen Experience Presenter: Raj Makkar, Lars Sondergaard, Helene Eltchaninoff October 31, 2016
Presentation TCT 2016 Controversy 3. Surgical Perspectives on Late Bioprosthetic Valve Durability Presenter: Raj Makkar, Lars Sondergaard, A. Pieter Kappetein October 31, 2016
Presentation TCT 2016 Flash Debate: Counterpoint 4D-CT Leaflet Imaging Findings Will Help to Direct Anticoagulation Therapy! Presenter: Raj Makkar, Lars Sondergaard October 31, 2016
Presentation TCT 2016 Flash Debate: Point 4D-CT Leaflet Thickening Is an Imaging Curiosity With No Clinical Relevance! Presenter: Raj Makkar, Lars Sondergaard, Ganesh Manoharan October 31, 2016
Presentation TCT 2016 Controversy 2. Global Clinical Trial Experiences on Bioprosthetic Leaflet Thickening/Thrombosis: Updates and Insights Presenter: Raj Makkar, Lars Sondergaard October 31, 2016
Presentation TCT 2016 Flash Debate: Counterpoint Cerebral Protection Is an Unnecessary and Costly Accessory! Presenter: Raj Makkar, Lars Sondergaard, Haim Danenberg October 31, 2016
Presentation TCT 2016 Flash Debate: Point Cerebral Protection Is a Must for All Patients! Presenter: Raj Makkar, Lars Sondergaard, Axel Linke October 31, 2016
Presentation TCT 2016 Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials Presenter: Raj Makkar, Lars Sondergaard, Samir R. Kapadia October 31, 2016